Endo, Inc. announced that it has begun shipping doxycycline for injection, USP 100 mg/vial, an AP-rated version of DOXY 100™.
"We're pleased to provide choices to healthcare providers and hospital pharmacies as they work to deliver quality patient care," said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo. "The doxycycline for injection strengthens our sterile injectable product portfolio and underscores our reputation as a reliable supplier of aseptic medicines."
According to IQVIA®, doxycycline for injection 100 mg vial sales were approximately $49 million for the 12 months ended September 30, 2024.
DOXY 100™ is a trademark of Fresenius Kabi.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!